NCT01767688View on ClinicalTrials.gov

A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 16, 2013

Primary Completion Date

March 1, 2013

Study Completion Date

March 7, 2013

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

MK-3102

Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01767688 - A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031) | Biotech Hunter | Biotech Hunter